Analysis of Liquidity Ratios
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Regeneron Pharmaceuticals Inc., liquidity ratios
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Current ratio | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 | |
| Quick ratio | 2.86 | 2.81 | 3.50 | 2.98 | 2.13 | |
| Cash ratio | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s current ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s quick ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s cash ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Current Ratio
Regeneron Pharmaceuticals Inc., current ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current assets | 9,779,100 | 7,689,100 | 6,447,600 | 4,335,030 | 3,180,188 | |
| Current liabilities | 2,697,400 | 2,096,600 | 1,442,800 | 1,135,483 | 1,241,495 | |
| Liquidity Ratio | ||||||
| Current ratio1 | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 | |
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| Abbott Laboratories | 1.72 | 1.44 | 1.62 | 2.26 | 4.02 | |
| AbbVie Inc. | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 | |
| Amgen Inc. | 1.81 | 1.44 | 2.79 | 5.49 | 4.11 | |
| Bristol-Myers Squibb Co. | 1.58 | 1.60 | 1.61 | 1.55 | 1.55 | |
| Eli Lilly & Co. | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 | |
| Gilead Sciences Inc. | — | 3.10 | 3.38 | 2.74 | 2.22 | |
| Illumina Inc. | 3.60 | 6.69 | 2.49 | 3.99 | 3.29 | |
| Johnson & Johnson | 1.21 | 1.26 | 1.47 | 1.41 | 2.47 | |
| Merck & Co. Inc. | 1.02 | 1.24 | 1.17 | 1.33 | 1.78 | |
| Pfizer Inc. | 1.35 | 0.88 | 1.57 | 1.35 | 1.25 | |
| Vertex Pharmaceuticals Inc. | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 | |
| Zoetis Inc. | 3.05 | 2.63 | 3.60 | 3.85 | 3.03 | |
| Current Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 1.57 | 1.73 | 1.82 | 2.10 | |
| Current Ratio, Industry | ||||||
| Health Care | — | 1.49 | 1.52 | 1.61 | 1.75 | |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).
1 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 9,779,100 ÷ 2,697,400 = 3.63
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s current ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Quick Ratio
Regeneron Pharmaceuticals Inc., quick ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cash and cash equivalents | 2,193,700 | 1,617,800 | 1,467,700 | 812,733 | 535,203 | |
| Marketable securities | 1,393,300 | 1,596,500 | 1,342,200 | 596,847 | 503,481 | |
| Accounts receivable, trade, net | 3,111,500 | 2,100,000 | 1,723,700 | 1,538,642 | 1,343,368 | |
| Accounts receivable, Sanofi, net | 404,700 | 260,600 | 226,400 | 193,684 | 92,989 | |
| Accounts receivable, other, net | 598,500 | 311,600 | 293,100 | 242,014 | 175,263 | |
| Total quick assets | 7,701,700 | 5,886,500 | 5,053,100 | 3,383,920 | 2,650,304 | |
| Current liabilities | 2,697,400 | 2,096,600 | 1,442,800 | 1,135,483 | 1,241,495 | |
| Liquidity Ratio | ||||||
| Quick ratio1 | 2.86 | 2.81 | 3.50 | 2.98 | 2.13 | |
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| Abbott Laboratories | 1.14 | 0.88 | 1.03 | 1.67 | 3.31 | |
| AbbVie Inc. | 0.60 | 2.91 | 0.78 | 0.89 | 1.14 | |
| Amgen Inc. | 1.30 | 1.01 | 2.44 | 4.98 | 3.68 | |
| Bristol-Myers Squibb Co. | 1.28 | 1.26 | 1.37 | 1.30 | 1.27 | |
| Eli Lilly & Co. | 0.85 | 0.68 | 1.20 | 0.91 | 0.98 | |
| Gilead Sciences Inc. | — | 2.86 | 3.15 | 2.52 | 1.78 | |
| Illumina Inc. | 3.18 | 6.00 | 2.23 | 3.43 | 2.75 | |
| Johnson & Johnson | 0.91 | 0.94 | 1.08 | 1.04 | 2.04 | |
| Merck & Co. Inc. | 0.58 | 0.78 | 0.72 | 0.83 | 1.24 | |
| Pfizer Inc. | 0.78 | 0.50 | 0.84 | 0.93 | 0.84 | |
| Vertex Pharmaceuticals Inc. | 4.02 | 3.33 | 3.19 | 2.94 | 2.06 | |
| Zoetis Inc. | 2.13 | 1.67 | 2.24 | 2.34 | 1.47 | |
| Quick Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 1.18 | 1.28 | 1.41 | 1.64 | |
| Quick Ratio, Industry | ||||||
| Health Care | — | 1.13 | 1.12 | 1.24 | 1.35 | |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).
1 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 7,701,700 ÷ 2,697,400 = 2.86
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s quick ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Cash Ratio
Regeneron Pharmaceuticals Inc., cash ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cash and cash equivalents | 2,193,700 | 1,617,800 | 1,467,700 | 812,733 | 535,203 | |
| Marketable securities | 1,393,300 | 1,596,500 | 1,342,200 | 596,847 | 503,481 | |
| Total cash assets | 3,587,000 | 3,214,300 | 2,809,900 | 1,409,580 | 1,038,684 | |
| Current liabilities | 2,697,400 | 2,096,600 | 1,442,800 | 1,135,483 | 1,241,495 | |
| Liquidity Ratio | ||||||
| Cash ratio1 | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 | |
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| Abbott Laboratories | 0.60 | 0.38 | 0.45 | 1.08 | 2.82 | |
| AbbVie Inc. | 0.30 | 2.56 | 0.47 | 0.59 | 0.66 | |
| Amgen Inc. | 0.91 | 0.69 | 2.17 | 4.62 | 3.40 | |
| Bristol-Myers Squibb Co. | 0.83 | 0.84 | 0.83 | 0.71 | 0.72 | |
| Eli Lilly & Co. | 0.29 | 0.21 | 0.68 | 0.55 | 0.55 | |
| Gilead Sciences Inc. | — | 2.50 | 2.84 | 2.19 | 1.29 | |
| Illumina Inc. | 2.79 | 5.13 | 1.95 | 2.88 | 2.21 | |
| Johnson & Johnson | 0.59 | 0.54 | 0.63 | 0.60 | 1.59 | |
| Merck & Co. Inc. | 0.30 | 0.47 | 0.40 | 0.46 | 0.83 | |
| Pfizer Inc. | 0.47 | 0.26 | 0.59 | 0.66 | 0.57 | |
| Vertex Pharmaceuticals Inc. | 3.55 | 2.85 | 2.83 | 2.59 | 1.81 | |
| Zoetis Inc. | 1.66 | 1.07 | 1.39 | 1.43 | 0.65 | |
| Cash Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 0.81 | 0.90 | 1.01 | 1.23 | |
| Cash Ratio, Industry | ||||||
| Health Care | — | 0.73 | 0.72 | 0.85 | 0.94 | |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).
1 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,587,000 ÷ 2,697,400 = 1.33
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Regeneron Pharmaceuticals Inc.’s cash ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |